Literature DB >> 27595545

Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.

Hetanshi Naik1, Mikayla Stoecker2, Saskia C Sanderson3, Manisha Balwani4, Robert J Desnick5.   

Abstract

BACKGROUND: The acute hepatic porphyrias (AHPs) are rare inborn errors of heme biosynthesis, characterized clinically by life-threatening acute neurovisceral attacks. Patients with recurrent attacks have a decreased quality of life (QoL); however, no interactive assessment of these patients' views has been reported. We conducted guided discussions regarding specific topics, to explore patients' disease experience and its impact on their lives.
METHODS: Sixteen AHP patients experiencing acute attacks were recruited to moderator-led online focus groups. Five groups (3-4 patients each) were conducted and thematic analyses to identify, examine, and categorize patterns in the data was performed.
RESULTS: All patients identified prodromal symptoms that began days prior to acute severe pain; the most common included confusion ("brain fog"), irritability, and fatigue. Patients avoided hospitalization due to prior poor experiences with physician knowledge of AHPs or their treatment. All patients used complementary and alternative medicine treatments to avoid hospitalization or manage chronic pain and 81% reported varying degrees of effectiveness. All patients indicated their disease impacted personal relationships due to feelings of isolation and difficulty adjusting to the disease's limitations.
CONCLUSION: Patients with recurrent attacks recognize prodromal warning symptoms, attempt to avoid hospitalization, turn to alternative treatments, and have markedly impaired QoL. Counseling and individualized support is crucial for AHP patients with recurrent attacks.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute hepatic porphyria; Acute intermittent porphyria; Focus groups; Psychosocial experiences; Quality of life

Mesh:

Substances:

Year:  2016        PMID: 27595545      PMCID: PMC5083146          DOI: 10.1016/j.ymgme.2016.08.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  26 in total

Review 1.  Modern diagnosis and management of the porphyrias.

Authors:  Shigeru Sassa
Journal:  Br J Haematol       Date:  2006-09-04       Impact factor: 6.998

Review 2.  Porphyria and its neurologic manifestations.

Authors:  Jennifer A Tracy; P James B Dyck
Journal:  Handb Clin Neurol       Date:  2014

3.  Self-rated psychosocial consequences and quality of life in the acute porphyrias.

Authors:  L M Millward; P Kelly; A Deacon; V Senior; T J Peters
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

4.  Barriers to and motivators for physical activity among people with Type 2 diabetes: patients' perspectives.

Authors:  L P Lidegaard; N Schwennesen; I Willaing; K Faerch
Journal:  Diabet Med       Date:  2016-07-09       Impact factor: 4.359

Review 5.  Stress and health: major findings and policy implications.

Authors:  Peggy A Thoits
Journal:  J Health Soc Behav       Date:  2010

6.  Social interaction experiences of adults with Moebius Syndrome: a focus group.

Authors:  Kathleen R Bogart; Linda Tickle-Degnen; Matthew S Joffe
Journal:  J Health Psychol       Date:  2012-01-18

7.  Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.

Authors:  R Kauppinen; P Mustajoki
Journal:  Medicine (Baltimore)       Date:  1992-01       Impact factor: 1.889

8.  Best practice guidelines on clinical management of acute attacks of porphyria and their complications.

Authors:  Penelope Stein; Mike Badminton; Julian Barth; David Rees; M Felicity Stewart
Journal:  Ann Clin Biochem       Date:  2013-05       Impact factor: 2.057

Review 9.  Acute Hepatic Porphyria.

Authors:  D Montgomery Bissell; Bruce Wang
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

Review 10.  An update of clinical management of acute intermittent porphyria.

Authors:  Elena Pischik; Raili Kauppinen
Journal:  Appl Clin Genet       Date:  2015-09-01
View more
  24 in total

1.  Psychosocial issues in erythropoietic protoporphyria - the perspective of parents, children, and young adults: A qualitative study.

Authors:  Hetanshi Naik; Shruti Shenbagam; Allysa Marie Go; Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-26       Impact factor: 4.797

Review 2.  Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).

Authors:  Herbert L Bonkovsky; Natalia Dixon; Sean Rudnick
Journal:  Mol Genet Metab       Date:  2019-03-06       Impact factor: 4.797

Review 3.  Acute hepatic porphyrias: Recommendations for evaluation and long-term management.

Authors:  Manisha Balwani; Bruce Wang; Karl E Anderson; Joseph R Bloomer; D Montgomery Bissell; Herbert L Bonkovsky; John D Phillips; Robert J Desnick
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

Review 4.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 5.  Acute hepatic porphyrias: Current diagnosis & management.

Authors:  Karl E Anderson
Journal:  Mol Genet Metab       Date:  2019-07-05       Impact factor: 4.797

6.  Acute intermittent porphyria: prevalence of pathogenic HMBS variants in China, and epidemiological survey in Hebei Province, China.

Authors:  Liyan Ma; Yu Tian; Xuan Qi; Pei Li; Jie Li; Qing Teng; Yuelin Ma; Songyun Zhang
Journal:  Ann Transl Med       Date:  2022-05

Review 7.  Porphyric Neuropathy: Pathophysiology, Diagnosis, and Updated Management.

Authors:  Mohamed Kazamel; Robert J Desnick; John G Quigley
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-07       Impact factor: 5.081

8.  Acute intermittent porphyria: A case report

Authors:  José Bustos; Ledmar Vargas; Ricardo Quintero
Journal:  Biomedica       Date:  2020-03-01       Impact factor: 0.935

Review 9.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

10.  Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.

Authors:  Paolo Ventura; Herbert L Bonkovsky; Laurent Gouya; Paula Aguilera-Peiró; D Montgomery Bissell; Penelope E Stein; Manisha Balwani; D Karl E Anderson; Charles Parker; David J Kuter; Susana Monroy; Jeeyoung Oh; Bruce Ritchie; John J Ko; Zhaowei Hua; Marianne T Sweetser; Eliane Sardh
Journal:  Liver Int       Date:  2021-11-16       Impact factor: 8.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.